ClinicalTrials.gg
CompletedNCT01398410Updated Dec 21, 2015Results posted

Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)

A Phase 2/3 interventional study of Rabeprazole and Rabeprazole in Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin, sponsored by Eisai Co., Ltd.. Completed at 50 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-12-21.

Sponsored by Eisai Co., Ltd. · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
405
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Stomach Ulcer with a site in Japan — none open to participants now, none under way, none of them phase 3. Stomach Ulcer · Japan.

Enrollment
10th of 20
405 · median 400
Started
2011
with 7 others
Phase 2/3
3 of 29
none open now
Registered
12th of 29
by date
Lead sponsor
4 of 29
Eisai Co., Ltd.

Among the 29 studies in Stomach Ulcer with a site in Japan, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is one of 8 that started in 2011, is one of 3 in phase 2/3, and was the 12th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

None of the 29 studies in Stomach Ulcer with a site in Japan is open now. The open studies under Stomach Ulcer, anywhere →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Stomach Ulcer with a site in Japan as a file.
02

Study summary

The primary objective of this study to examine the long-term safety of rabeprazole 5 mg or 10 mg tablets administered once daily in participants who were confirmed to have no recurrence of gastric or duodenal ulcer by endoscopic examination at the end of 24 weeks of treatment in the E3810-J081-308 (NCI01397448) [Double-Blind Phase] study. From a total of 420 participants who completed the E3810-J081-308 study, 328 entered the E3810-J081-309 (NCT01398410) study.

Read the detailed description

The E3810-J081-309 consisted of two arms: the long-term rabeprazole groups (participants from the rabeprazole 5 or 10 mg arm of the E3810-J081-308 study who entered the rabeprazole 5 mg or 10 mg arm of the E3810-J081-309 study) and the newly-initiated rabeprazole groups (participants from the teprenone 150 mg arm of the E3810-J081-308 study who entered the rabeprazole 5 mg or 10 mg arm of the E3810-J081-309 study).

03

Conditions studied

  • Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin

Keywords

  • Rabeprazole
  • proton pump inhibitor
  • Acetylsalicylic Acid
  • Aspirin
  • Gastric Ulcer
  • Duodenal Ulcer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed to have no recurrence of gastric or duodenal ulcer by endoscopy at the end of 24 weeks of treatment in study E3810-J081-308.
  • Need to continue receiving low-dose aspirin (81 mg/day or 100 mg/day) during this study.

Exclusion criteria

Exclusion Criteria

-Confirmed to have a recurrence of gastric or duodenal ulcer at the end of 24 weeks of treatment in study E3810-J081-308 (at the start of this trial) and thus are withdrawn from the trial.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
405 participants (actual)

Study arms

  • Experimental
    Rabeprazole 5 mg

    Drug: Rabeprazole

  • Experimental
    Rabeprazole 10 mg

    Drug: Rabeprazole

Interventions

  • Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily

    Also known as: E3810, Pariet/Aciphex

  • Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily

    Also known as: E3810, Pariet/Aciphex

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment Emergent Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a participant administered with the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening (ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). In this study, treatment emergent AEs (defined as an AE (serious/non-serious) that started/increased in severity on/after the first dose of study drug up to 30 days after the final dose of study drug) were assessed. The data is presented as percentage of participants with treatment emergent AEs.

    Time frame: For each participant, from administration of first dose of study drug (rabeprazole) up to 30 days from administration of last dose of study drug (rabeprazole) or up to 76 weeks (including data from the Double-Blind Phase)

Secondary outcomes

  1. Cumulative Recurrent Rate of Gastric or Duodenal Ulcers

    Mucosal injuries with a white coat measuring greater than or equal to 3 mm in diameter was diagnosed as ulcers. When ulcer was confirmed by endoscopic examination during the trial, it was regarded as recurrence of ulcer and the trial was discontinued for the participant involved. The presence or absence of ulcer recurrence was determined by the endoscopy central review panel that were blinded to the investigators' assessments. Cumulative recurrent rate was estimated by the Kaplan-Meier method. The data is presented as percentage of participants with cumulative recurrent rate of gastric or duodenal ulcers.

    Time frame: Baseline, Week 12, Week 24, Week 52, and Week 76 (including data from the Double-Blind Phase)

07

Results

Posted Nov 16, 2015

Participant flow

Participant flow — Overall Study
MilestoneRabeprazole 5 mgRabeprazole 10 mg
Started201204
Completed143148
Not completed5856
Withdrew: Adverse event1216
Withdrew: Participants choice811
Withdrew: Inadequate therapeutic effect20
Withdrew: Other3629

Outcome measures

PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a participant administered with the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening (ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug). In this study, treatment emergent AEs (defined as an AE (serious/non-serious) that started/increased in severity on/after the first dose of study drug up to 30 days after the final dose of study drug) were assessed. The data is presented as percentage of participants with treatment emergent AEs.

Time frame:
For each participant, from administration of first dose of study drug (rabeprazole) up to 30 days from administration of last dose of study drug (rabeprazole) or up to 76 weeks (including data from the Double-Blind Phase)
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs)
Percentage of participantsRabeprazole 5 mgRabeprazole 10 mg
Percentage of Participants With Treatment Emergent Adverse Events (AEs)77.183.8
SecondaryCumulative Recurrent Rate of Gastric or Duodenal Ulcers

Mucosal injuries with a white coat measuring greater than or equal to 3 mm in diameter was diagnosed as ulcers. When ulcer was confirmed by endoscopic examination during the trial, it was regarded as recurrence of ulcer and the trial was discontinued for the participant involved. The presence or absence of ulcer recurrence was determined by the endoscopy central review panel that were blinded to the investigators' assessments. Cumulative recurrent rate was estimated by the Kaplan-Meier method. The data is presented as percentage of participants with cumulative recurrent rate of gastric or duodenal ulcers.

Time frame:
Baseline, Week 12, Week 24, Week 52, and Week 76 (including data from the Double-Blind Phase)
Reported as:
Number · Percentage of participants
Cumulative Recurrent Rate of Gastric or Duodenal Ulcers
Percentage of participantsRabeprazole 5 mgRabeprazole 10 mg
Baseline (N=150, 151)0 (0 to 0)0 (0 to 0)
Week 12 (N=150, 151)1.3 (0.34 to 5.23)0 (0 to 0)
Week 24 (N=139, 142)2.8 (1.04 to 7.17)1.4 (0.35 to 5.51)
Week 52 (N=107, 121)3.7 (1.53 to 8.64)2.2 (0.72 to 6.75)
Week 76 (N=93, 96)3.7 (1.53 to 8.64)2.2 (0.72 to 6.75)

Adverse events

Collected over For each participant, from administration of first dose of study drug (rabeprazole) up to 30 days from administration of last dose of study drug or up to 76 weeks (including data from the Double-Blind Phase). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rabeprazole 5 mg—33/201 (16.4%)89/201 (44.3%)
Rabeprazole10 mg—30/204 (14.7%)99/204 (48.5%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventRabeprazole 5 mgRabeprazole10 mg
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2014/204
Angina pectorisCardiac disorders3/2011/204
CataractEye disorders2/2011/204
Coronary artery restenosisInjury, poisoning and procedural complications2/2010/204
Acute myocardial infarctionCardiac disorders1/2010/204
Cardiac failure chronicCardiac disorders1/2010/204
Mitral valve incompetenceCardiac disorders1/2010/204
Tricuspid valve incompetenceCardiac disorders1/2010/204
Vertigo positionalEar and labyrinth disorders1/2010/204
Diverticulum intestinal haemorrhagicGastrointestinal disorders1/2010/204
Most frequent other events
Most frequent other events
EventRabeprazole 5 mgRabeprazole10 mg
NasopharyngitisInfections and infestations64/20157/204
DiarrhoeaGastrointestinal disorders11/20116/204
ConstipationGastrointestinal disorders9/20116/204
Back painMusculoskeletal and connective tissue disorders14/20113/204
ContusionInjury, poisoning and procedural complications13/2017/204
EczemaSkin and subcutaneous tissue disorders6/20112/204

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Rabeprazole 5 mgRabeprazole 10 mgTotal
Mean69.4 ± 8.570.1 ± 9.369.8 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Rabeprazole 5 mgRabeprazole 10 mgTotal
Female4852100
Male153152305
08

Study locations

50 sites
  • Kasugai, Aichi, Japan
  • Nagoya, Aichi, Japan
  • Ichikawa, Chiba, Japan
  • Chikushino, Fukuoka, Japan
  • Kitakyushu, Fukuoka, Japan
  • Onga, Fukuoka, Japan
  • Maebashi, Gunma, Japan
  • Asahikawa, Hokkaido, Japan
  • Sapporo, Hokkaido, Japan
  • Tomakomai, Hokkaido, Japan
  • Itami, Hyogo, Japan
  • Kobe, Hyogo, Japan
  • Hitachi, Ibaraki, Japan
  • Fujisawa, Kanagawa, Japan
  • Kawasaki, Kanagawa, Japan
  • Sagamihara, Kanagawa, Japan
  • Yokohama, Kanagawa, Japan
  • Hitoyoshi, Kumamoto, Japan
  • Ebino, Miyazaki, Japan
  • Chikuma, Nagano, Japan
  • Matsumoto, Nagano, Japan
  • Suzaka, Nagano, Japan
  • Beppu, Oita, Japan
  • Yufu, Oita, Japan
  • Daito, Osaka, Japan
  • Hirakat, Osaka, Japan
  • Matsubara, Osaka, Japan
  • Takatsuki, Osaka, Japan
  • Yao, Osaka, Japan
  • Karatsu, Saga, Japan
  • Ureshino, Saga, Japan
  • Izumo, Shimane, Japan
  • Hamamatsu, Shizuoka, Japan
  • Ohtawara, Tochigi, Japan
  • Mitaka, Tokyo, Japan
  • Setagaya, Tokyo, Japan
  • Shinjuku, Tokyo, Japan
  • Fukuoka, Japan
  • Gifu, Japan
  • Kitakyushu, Japan
  • Kochi, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Miyazaki, Japan
  • Nagano, Japan
  • Nagasaki, Japan
  • Oita, Japan
  • Osaka, Japan
  • Saga, Japan
  • Shizuoka, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Dec 2013 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2011
First posted
Jul 20, 2011
Start
Dec 2011
Primary completionActual
Dec 2013
CompletionActual
Feb 2014
Results first posted
Nov 16, 2015
Last update
Dec 21, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01398410
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Jul 20, 2011
Start date
Dec 2011
Primary completion
Dec 2013
Completion
Feb 2014
Results posted
Nov 16, 2015
Last update
Dec 21, 2015

Study contacts

Nobuyuki Sugisaki
study director · Japan/Asia Clinical Research Product Creation Unit
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion